Business Wire

NJ-SEMPERIS

4.5.2021 15:02:07 CEST | Business Wire | Press release

Share
Semperis Enhances the Industry’s Most Comprehensive Active Directory Protection Platform with Continuous Security Validation

Semperis , the pioneer of identity-driven cyber resilience for enterprises, today announced the general availability of Directory Services Protector (DSP) v3.5, which includes DSP Intelligence, a new module that provides automated security assessments of Microsoft Active Directory (AD). DSP Intelligence proactively uncovers dangerous vulnerabilities that arise from external threat actors, systemic weaknesses in default identity and access settings, and even internal configuration drift that leads to security regression.

The company also announced enhancements to Active Directory Forest Recovery (ADFR), the only disaster recovery product for AD purpose-built to combat cyberattacks. New ADFR capabilities include unique backup set encryption keys, advanced forensics search, and extended support for SAML and MFA authentication.

The continuous security assessment capabilities now available in DSP Intelligence address the skyrocketing proliferation of cyberattacks—including the infamous SolarWinds supply-chain attack and the Hafnium attack on Microsoft Exchange—that target identity systems, especially AD. As the gatekeeper to critical applications and data in 90% of organizations worldwide, AD is a common access vector for attackers and extremely complex to secure given its constant flux, sheer number of settings, and the increasingly sophisticated threat landscape. Findings from companies using Semperis’ free Purple Knight security assessment tool revealed that even large organizations with significant investments in security resources are failing to close critical gaps in AD, scoring an average of 61%, with Kerberos authentication being the top risk area.

“Active Directory is a critical piece of most enterprises’ IT infrastructure but is notoriously difficult to keep secure,” said Darren Mar-Elia, Vice President of Products at Semperis. “Not only are its settings complex, but both AD itself and attack paths are constantly evolving. Organizations must be able to ensure their directory services are secure on a continual basis—not just at a point in time—while actively testing against the latest indicators for new attacks and threats. DSP Intelligence is designed to provide a larger range of security indicators and advance pre-attack tests to harden AD against new adversary TTPs and spot your weaknesses before attackers do. The threat hunting capabilities have also proven to be extremely helpful for organizations in post-breach scenarios to understand how attackers broke in and how to close backdoors for good.”

A growing number of breaches involve the exploitation of suboptimal AD configurations to allow attackers to gain a foothold within target networks, access sensitive resources, and deploy malware. To get ahead of attackers, DSP Intelligence continuously queries an organization’s AD environment and performs a comprehensive set of tests against the most common and effective attack vectors that correlate to known security frameworks such as the MITRE ATT&CK.

With the addition of DSP Intelligence, Semperis further establishes DSP as the industry’s most comprehensive AD threat detection and response platform. Semperis also updated the complementary modules, DSP Essential and DSP Advanced, which address foundational directory security and operational use cases:

  • DSP Essential – AD change tracking and rollback
  • DSP Advanced – Autonomous threat protection and response
  • DSP Intelligence – Security validation and breach prevention

To see DSP Intelligence in action, watch the five-minute video overview: https://pages.semperis.com/dsp-intelligence-video-intro/

For more information about DSP and ADFR, visit the product pages below:

About Semperis

For security teams charged with defending hybrid and multi-cloud environments, Semperis ensures integrity and availability of critical enterprise directory services at every step in the cyber kill chain and cuts recovery time by 90%. Purpose-built for securing Active Directory, Semperis’ patented technology protects over 40 million identities from cyberattacks, data breaches, and operational errors. The world’s leading organizations trust Semperis to spot directory vulnerabilities, intercept cyberattacks in progress, and quickly recover from ransomware and other data integrity emergencies. Semperis is headquartered in New Jersey and operates internationally, with its research and development team distributed between San Francisco and Tel Aviv.

Semperis hosts the award-winning Hybrid Identity Protection conference (www.hipconf.com ). The company has received the highest level of industry accolades and was recently ranked the fourth fastest-growing company in the tri-state area and 35th overall in Deloitte’s 2020 Technology Fast 500™ . Semperis is accredited by Microsoft and recognized by Gartner.

Twitter https://twitter.com/SemperisTech
LinkedIn https://www.linkedin.com/company/semperis
Facebook https://www.facebook.com/SemperisTech
YouTube https://www.youtube.com/channel/UCycrWXhxOTaUQ0sidlyN9SA

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release

Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me

BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release

Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro

Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release

Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely

MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release

The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav

New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release

Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye